Google Photos AI Remix: Are Your Memories Still Real?
Remix prioritizes fun and ease of use over creative control
The feature raises concerns over how we view our memories.
Google Photos is primed to significantly change the way we interact with our memories, thanks to an experimental new AI-powered 'Remix' feature that will let you transform any still images into entertaining video clips using AI. While this sounds like a fun new way to enjoy our photos, for me, it also raises questions about the authenticity of our memories and whether such a feature is really appropriate for Google Photos.
Early signs of the Remix feature were first spotted in the Google Photos app a couple of months ago, focused mainly on transforming photos into various artistic styles, but now a new report from Android Authority , reveals Google's demo of a new image-to-video function, suggesting that the feature is getting closer to release.
Google's Remix feature turns still images into fun videos with AI. GOOGLE/ANDROID AUTHORITY
The demo video, unearthed by software sleuth AssembleDebug , shows a still image of a cute dog, accompanied by two human friends in the park. Remix then transforms this image into a celebration including natural movements from all three participants, with the addition of applause and falling confetti.
https://x.com/AssembleDebug/status/1942941681503846437
Introductory text below the clip states, 'Simply choose a photo, pick a fun prompt to apply, and see your photo transform,' displayed above a large 'Try now' button implying that Google is preparing to introduce the new Remix feature to users imminently. According to previous discoveries reported on by Android Authority , these 'fun prompts' will include 'Subtle Movements, ' 'Go Wild,' and 'I'm Feeling Lucky,' suggesting that users will have only limited control over the videos they create.
With the Pixel 10-series launch just weeks away, the release of Remix could be strategically timed to showcase the capabilities of Google's latest Pixel devices. However, there's nothing in the code to suggest when, or for whom, the feature will eventually become available. Perhaps it will launch as a Pixel 10 exclusive, or for Google One subscribers only: we'll have to wait and see. Not The Same As Gemini's Veo 3 Image-To-Video?
Google adds image-to-video capabilities to Gemini for Gemini Pro and Gemini Ultra subscribers GOOGLE
Remix appears, at first glance, to offer similar functionality to other image-to-video AI applications, including the version powered by Google's own Veo 3 model, recently made available to Gemini Pro and Gemini Ultra subscribers in the Gemini app. However, there seem to be some important differences between the two, not least being the fact that Veo 3 allows you to type any text prompt you like when generating a video rather than forcing you to pick from a list. Veo 3 can also generate audio for your AI clips, something which isn't mentioned as a feature of Remix.
However, I think Remix's inherent limitations could be vital in maintaining Google Photos' core usage as a place for storing, reliving and sharing memories. Is Google Photos the right place for AI Video?
Google has a history of using the latest available technologies, including AI, to enhance and repurpose the photos and videos in our libraries by automatically-generating animations and short videos and collating our most interesting memories into 'Moments.'
However, the Remix feature appears to take things a step further by encouraging users to turn their photos into videos of moments that never actually happened.
I feel Google Photos should be a place for storing real memories rather than a platform for creating synthetic content. Google Photos is pretty good at separating out different types of content, such as screenshots and documents, so it's reasonable to hope it will do the same with AI-generated videos. However, if Remix AI-videos start appearing in Google's automatically-generated 'Moments,' I think we'll have a problem — especially if they become difficult to distinguish from reality.
Remix runs the risk of blurring the lines between genuine memories and what many would consider 'AI slop.' I'm sure there's plenty of fun to be had in sharing short AI-generated clips, but I wouldn't want them clogging up my photo library.
Much will depend on the details of how Google implements Remix and how Google Photos curates these AI videos alongside our genuine photos and videos. Would you use Remix? Let me know in the comments below.
Follow @paul_monckton on Instagram. Forbes Google Photos Gives New AI Photo Editor To All — And It's A Genius Move By Paul Monckton Forbes Google Photos Is Getting Smarter About Deleting Your Worst Pictures By Paul Monckton
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
These 2 Momentum Stocks Got a Bullish Nod — Here's Why They Could Reach New Highs
Buying into rising stocks is a natural impulse – and it's a viable investing strategy. Momentum investing, as it's called, is the art of finding and following the market's upward trends. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Of course, every investing style has its boosters and its bummers, and both sides usually have strong arguments in their favor. The key to success is finding balance, and remembering that while past performance won't guarantee a future return, it can still provide useful indications of where a stock is heading. With that in mind, let's dive into a pair of momentum stocks that are currently catching investors' attention. Using the TipRanks database, we've zeroed in on two names that have not only gained steam lately, but have also received bullish endorsements from at least one Street analyst. Let's take a look. BridgeBio Pharma (BBIO) The first momentum stock on our list today is BridgeBio, a biopharmaceutical company with a focus on genetic diseases that are both rare and serious. More specifically, BridgeBio has chosen disease targets with what it describes as 'clear genetic drivers'; that is, it is developing drug candidates to treat diseases that are genetically linked to single mutations. BridgeBio has chosen a rich field in which to work, as it can choose from more than 10,000 genetic diseases that meet its target criteria – and they impact tens of millions of patients globally. More importantly, this group of diseases has relatively few FDA-approved medications, giving BridgeBio plenty of openings. BridgeBio bases its development work on its proprietary drug development platform, looking for novel genetic diseases to target and then creating new medicines to address symptoms and improve patient outcomes. The company follows this development stage by moving a drug candidate from a successful clinical trial series and into the regulatory process, with commercialization being the final goal. BridgeBio reached that goal late last year. This past November, the company received FDA approval of its drug acoramidis for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM), a disease that affects the heart muscle. Treatment with acoramidis was shown in clinical trials to reduce death and hospitalization from the disease, with statistically significant improvements in patients under treatment. BridgeBio is marketing the new drug under the brand name Attruby, and 1Q25 was the company's first full quarter of commercialization efforts. The company is still investigating acoramidis in the clinical trial program, where it is the subject of the Phase 3 ACT-EARLY study, testing whether the drug is useful in preventing asymptomatic patients who carry the pathogenic TTR variant from developing the active disease. Turning to the company's financial side, we find that BridgeBio's 1Q25 earnings release showed $116.6 million in total revenues, of which $36.7 million was net product revenue derived from sales of Attruby in the US following the drug's commercial launch. The balance of the company's revenue came from license and services income. Compared to the prior-year quarter, this segment of the revenue was down by $131.2 million, leading to the total revenue year-over-year decline of 45%, although the total haul actually beat Street expectations by $58 million, aided by Atturby's better-than-expected debut. BridgeBio ran a net loss in 1Q25, of 88 cents per share, yet this was 5 cents per share better than had been expected. Investors have liked the story here and the stock shows a strong gain for the year-to-date, up ~74%. BridgeBio has caught the attention of Oppenheimer analyst Trevor Allred, who is taking a more bullish stance on the shares in light of Attruby's successful commercialization. Allred writes, 'We've been wrong on BBIO since our initiation—Bridgebio's team has executed Attruby's launch superbly, and shares have been supported by commercial outperformance and a look-ahead to clinical catalysts at YE. Our trepidation around 2029 generic entry has not mattered for 2025 stock performance. We expect share outperformance to continue as 2025 Attruby sales clear consensus estimates, and we expect commercial success to be compounded by positive clinical results from ADH1 and LGMD2i clinical trials around YE. Our concerns regarding long-term revenue durability remain, but BBIO has time to demonstrate real-world datasets demonstrating benefit over tafamidis should generics become available in 2029.' Allred follows these comments with an upgrade from Perform (i.e., Neutral) to Outperform (i.e., Buy) rating for BBIO, and a $60 price target that implies a one-year upside potential of 26%. (To watch Allred's track record, click here) Overall, this stock has earned a Strong Buy consensus rating from the Street, based on 18 recent reviews that have a lopsided breakdown of 17 Buys to 1 Hold. The shares are priced at $47.69, and their $62.75 average target price suggests that the stock will gain 31.5% by this time next year. (See BBIO stock forecast) So-Young International (SY) Next up on our list of momentum stocks is So-Young, a Chinese company. The firm that operates a social media platform, linked to the medical aesthetics industry, and connecting the varied consumers, professionals, and medical service providers in the aesthetics sector. The platform makes available reliable and trustworthy information on a carefully vetted and curated network of medical aesthetic providers. The service platform focuses on content distribution in China, making use of major social media networks and other targeted media platforms. Social media and medical aesthetics are both growth industries, and So-Young is building a brand image based on user trust, an extensive reach, and valuable data insights. So-Young's user base can trade information on clinics, the latest treatment trends in aesthetics, and the quality of treatment, all permitting better patient decisions – and based on the trust engendered by sharing personal experiences. The company is working to expand its network, to add additional medical fields such as dentistry, dermatology, ophthalmology, and basic physical exams. The service is focused on China, and the company is based in Beijing. In its financial release for 1Q25, So-Young reported important gains in the number of active users on its network and the number of verified paid visits. The active users – defined as those who had visited an aesthetic clinic at least once in the previous 12 months – totaled more than 75,500, a massive gain from the 8,000 reported in the prior-year period. The gain in verified paid visits was similar, with 45,500 in 1Q25 compared to 4,600 in 1Q24. The company reported Q1 revenue at the high end of its previously published guidance range, with a top line of RMB297.3 million (approximately US$41 million) compared with RMB318.3 million in the first quarter of 2024, a figure that beat Street expectations by $0.8 million. The shares have been on a huge runup, up 411% this year, the bulk of the gains generated over the past month and this Chinese momentum stock has come to the attention of Citi analyst Nelson Cheung, who is impressed by the company's recent growth. Cheung says of So-Young and its prospects, 'Since launch in Nov 2024, SoYoung Clinic has quickly expanded with 31 centers in major cities (Beijing, Shanghai, Shenzhen) by end-Jun, verifying SY's strength in 1) differentiating brand position for quality standardized service and value-for-money mindshare for mass public; 2) increasing pricing power over procurement as it scales up; 3) effective online private domain cross-selling for accurate targeting and site selection; 4) proven execution for profitable store management with ~80% aesthetic centers generating +ve op cash flow in 1Q. We see meaningful catalysts to drive stock price further if: 1) improving monthly sales for flagship stores in Jun (e.g. Beijing Baoli); 2) potential exploration of full managed franchising model by end 2025; 3) solid exclusive product pipeline until 2027E.' (To watch Cheung's track record, click here) Looking forward, Cheung rates this stock as a Buy, with a $5.50 price target that suggests a one-year gain for the stock of 30%. Cheung's is the only analyst review on file for this stock, which is currently trading for $4.24. (See SY stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
12 minutes ago
- Business Wire
Pluto Labs' 'Strategic Efficiency' AI Outperforms Google & Anthropic Models at a Fraction of the Cost
SEOUL, South Korea--(BUSINESS WIRE)--In the global race to create an 'AI Scientist' capable of independent scientific discovery, Korean startup Pluto Labs is making significant waves. While tech giants like Google and Anthropic define competitive strength by sheer computing power, Pluto Labs introduces 'Scinapse AI,' a groundbreaking model that develops a more effective AI Scientist at just one-tenth of the usual computational cost, achieving overwhelming performance against top models in blind evaluations. Surprising results: A startup's AI now leads in scientific idea generation Share Pluto Labs pioneers a 'Strategic Efficiency' architecture, mirroring how human scientists optimize research. Instead of brute-force computing (like Google's 'Co-scientist'), Scinapse AI smartly delegates inefficient tasks, such as sifting through vast data, to its existing Scinapse academic search system (used by 170,000 researchers). This allows the AI to focus exclusively on creative reasoning and generating new ideas, leading to unparalleled practicality and cost-efficiency. Scinapse AI's superior performance was proven in blind evaluations judged by direct competitors' AI models (OpenAI O3, Anthropic's Claude 4 Opus, and Google's Gemini 2.5 Pro). Scinapse AI consistently ranked #1 in 'Plausibility' (how realistic and sound an idea is) and 'Testability' (how easily an idea can be experimentally validated) across 61 diverse scientific topics. This confirms Scinapse AI delivers "real scientific hypotheses that are practical to implement and can be experimentally validated within 3-5 years," a significant leap from 'plausible fiction' to 'actionable scientific research.' Pluto Labs has developed a robust system to eliminate AI 'hallucinations' (false information), a critical barrier in scientific AI. All Scinapse AI ideas are strictly grounded in a database of 260 million academic papers. The system dynamically refines searches for highly accurate data and rigorously cross-references ideas against the database to guarantee genuine novelty, identifying truly new scientific insights. "It provides the most complete answer to the question that challenges researchers most: 'Is this idea truly new?'" said Professor Changshin Jo of POSTECH."The AI completes a literature review in minutes that would take a human researcher days or weeks, and with higher accuracy. This is not just an idea-generation tool; it's an innovation that fundamentally changes the starting point of research planning." With cumulative funding of 5 billion KRW (~$3.6M USD), Pluto Labs is uniquely positioned to disrupt the global 'AI Scientist' race. Its 'efficiency' and 'practicality' approach, combined with its established Scinapse platform, sets it apart. "The fact that a small Korean startup has proven superior to Google in an objective benchmark is more than just a technical achievement—it's a symbolic event for innovative leadership," said Simon Kim, CEO of Hashed."It demonstrates that success in advanced AI can be achieved through creative problem-solving and strategic design, not just infinite capital. This is a significant milestone that points to the future direction for the global AI ecosystem, suggesting a new path for AI agent development." Scinapse AI is slated for official global launch in Q3 2025. About Pluto Labs: Pluto Labs is a Seoul-based Research Intelligence service company founded in 2019 that specializes in AI-powered scientific research tools. The company operates Scinapse, a comprehensive academic search platform used by over 170,000 researchers worldwide. Scinapse AI, launching in Q3 2025, is a next-generation AI scientist system that generates research ideas with high scientific validity through a hybrid AI architecture while maintaining cost efficiency. The company has raised a cumulative 5 billion KRW (~$3.6M USD) in funding from investors including Hashed, JB Investment, HG Initiative, and POSCO Investment. Pluto Labs is committed to leading global research innovation through accessible AI solutions.
Axios
12 minutes ago
- Axios
Exclusive: Drone-printer Firestorm eyes expansion after $47 million round
Firestorm Labs plans to move into a larger production facility, grow its fleet of airliftable xCell factories and cook up additional drone designs on the heels of a $47 million Series A. Why it matters: The California-based company is 3D printing the types of weapons and tools that define the Russia-Ukraine war. It's also inked contracts with the U.S. Defense Department, including one with the Air Force worth as much as $100 million. Follow the money: The round was led by New Enterprise Associates. Washington Harbour Partners and the investing arms of Lockheed Martin and Booz Allen Hamilton are among the other backers. The total includes $12 million in venture debt from JPMorgan. What they're saying: "We're building out the decentralized factory of the future," Firestorm CEO Dan Magy told Axios. "We want to be that manufacturing layer." The company has multiple drones in the works, ranging from Group 1 to Group 3. Tempest is its original offering. Zoom in: Firestorm this month said it secured exclusive distribution rights from HP for its Multi Jet Fusion 3D printing technologies. The arrangement is a "game-changer," according to Firestorm's chief technology officer, Ian Muceus. "We're excited to keep pushing boundaries, fine-tuning print settings, developing new materials, and maximizing throughput, material properties, and lightweighting."
